Business Context and Reporting Period
This Form 8-K is a current report filed by Klotho Neurosciences, Inc. (not Greenland Mines Ltd) on July 16, 2025, with a signature date of July 22, 2025. The registrant is a Delaware corporation and an emerging growth company. The filing discloses the entry into a material definitive agreement and provides Regulation FD disclosure regarding a press release issued on July 22, 2025.
Key Financial Metrics
This filing does not contain audited financial statements, revenue, profit, cash flow, or liquidity metrics. The only financial figures disclosed relate to the terms of a new licensing agreement:
- Initial License Fees: Scaled fees ranging from $250,000 for the first gene therapy product to $500,000 for the third product.
- Royalties: The Company will pay a 2% royalty on revenue from all products created using the licensed platform.
Material Changes
The primary material change is the execution of a Terms of Agreement with AAVnerGene Inc. on July 16, 2025. This agreement grants Klotho Neurosciences the exclusive and global right to use AAVnerGene's AAVone platform for the development, manufacturing, and commercialization of gene therapy products based on human Klotho gene isoforms. The agreement covers three specific clinical programs.
Guidance, Outlook, and Risks
The filing includes standard forward-looking statements regarding future commercial operations, clinical trial stages, and financial projections. Management notes that actual results may differ materially due to risks such as the inability to implement business plans, regulatory changes, and competitive pressures. The filing explicitly states that the press release information is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934.
Investor Verification Checklist
- Verify the discrepancy between the requested company name ("Greenland Mines Ltd") and the actual registrant ("Klotho Neurosciences, Inc.") in the source text.
- Review the full Terms of Agreement (Exhibit 4.1) for detailed payment schedules and termination clauses not fully summarized in the 8-K.
- Confirm the status of the three clinical programs mentioned in the agreement.
- Assess the impact of the 2% royalty obligation on future gross margins for any successful commercialized products.
- Check the press release (Exhibit 99.1) for additional context on the strategic rationale for the partnership.